Business
MYND Life Sciences Inc. Provides Default Status Report
Vancouver, British Columbia--(Newsfile Corp. - April 25, 2023) - MYND Life Sciences (CSE: MYND...
About this update from Mynd Life Sciences Inc
[{"type":"text","content":"MYND Life Sciences Inc. Provides Default Status ReportVancouver, British Columbia--(Newsfile Corp. - April 25, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) (\"MYND\" or the \"Company\"), a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless neurological diseases, today announced details regarding its Management Cease Trade Order. In accordance with the alternative information guidelines set out in National Policy 12-203 - Management Cease Trade Orders (\"NP 12-203\") MYND is giving the following update:On March 1, 2023, the Company announced that it applied for a management cease trade order (\"MCTO\") with the applicable securities regulatory authorities in Canada on the basis that the Company would be unable to file its Annual Audited Financial Statement, the Required Filing, for the year ended October 31, 2022 by the applicable filing deadlines. The MCTO was issued on March 1, 2023 and restricts all trading in securities of the Company, whether direct or indirect, by the Chief Executive Officer and Chief Financial Officer of the Company. The MCTO does not affect the ability of other shareholders of the Company to trade their securities.The Company's management continues to work diligently to complete the Required Filing and following communication with the Auditor, anticipates that the Required Filing will be filed by April 28, 2023.The Company confirms that since the date of the Original Announcement: (i) other than as described above, there has been no material change to the information set out in the Original Announcement that has not been generally disclosed; (ii) there has been no failure by the Company in fulfilling its stated intentions with respect to satisfying the provisions of the alternative information guidelines set out in NP 12-203; (iii) there has not been any other specified default by the Company under NP 12-203; and (iv) there is no other material information concerning the affairs of the Company that has not been generally disclosed.ABOUT MYND LIFE SCIENCES INC.MYND Life Sciences Inc. is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel drug development, diagnostics and vaccines. MYND is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates its...